<DOC>
	<DOC>NCT01930773</DOC>
	<brief_summary>Patients undergoing percutaneous coronary intervention with a residual high platelet reactivity despite oral clopidogrel are at increased risk of ischaemic complications. The strategies to overcome the issue consist of switch to a more potent antiplatelet medications including prasugrel or ticagrelor. Economic constrains of many countries still do not allow wide reimbursement of newer antiplatelet agents. Therefore a strategy to personalise treatment according to genotype and phenotype characteristics of the patient may provide an attractive solution combining high clinical efficacy with low budget impact.</brief_summary>
	<brief_title>Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)</brief_title>
	<detailed_description />
	<mesh_term>Angina, Stable</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>age 1875 elective PCI acute coronary syndrome (troponin &gt; 1 x ULN), administration of glycoprotein IIb/IIIa inhibitors, chronic total occlusion, lesions with extensive calcifications requiring rotational atherectomy, platelet count &lt;70 000 /Âµl high bleeding risk, coronary bypass surgery in the previous 3 months, severe chronic renal failure (eGFR &lt; 30 mL/min) requirement for warfarin, dabigatran, apixaban, rivaroxaban history of stroke or TIA, weight &lt; 60 kg known bleeding diathesis, hematocrit of &lt; 30% or &gt;52% pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>clopidogrel</keyword>
	<keyword>prasugrel</keyword>
	<keyword>platelet function testing</keyword>
	<keyword>genotyping</keyword>
	<keyword>peri-procedural MI</keyword>
</DOC>